CN Patent

CN113880865A — 吡唑[1,5-a]吡啶类化合物及其制备方法与应用

Assigned to Shanghai Allist Medicine Polytron Technologies Inc · Expires 2022-01-04 · 4y expired

What this patent protects

本发明涉及下述通式(I)所示的吡唑[1，5‑a]吡啶类化合物、其制备方法、药物组合物及应用，式中R 1 、R 2 、R 3 、R 4 、R 5 、X、Y、Z如说明书中所定义。本发明所述吡唑[1，5‑a]吡啶类化合物能够有效抑制野生型RET、突变型RET特别是G810R突变型RET、以及KIF5B‑RET和CCDC6‑RET等RET融合，且安全性好，可用于治疗由RET介导的疾病，例如癌症和肠易激综合征。

USPTO Abstract

本发明涉及下述通式(I)所示的吡唑[1，5‑a]吡啶类化合物、其制备方法、药物组合物及应用，式中R 1 、R 2 、R 3 、R 4 、R 5 、X、Y、Z如说明书中所定义。本发明所述吡唑[1，5‑a]吡啶类化合物能够有效抑制野生型RET、突变型RET特别是G810R突变型RET、以及KIF5B‑RET和CCDC6‑RET等RET融合，且安全性好，可用于治疗由RET介导的疾病，例如癌症和肠易激综合征。

Drugs covered by this patent

Patent Metadata

Patent number
CN113880865A
Jurisdiction
CN
Classification
—
Expires
2022-01-04
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Allist Medicine Polytron Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.